Supplement Manufacturer Tax Planning: R&D Credits and Deductions

May 19, 2026

By: Wiss Team

Wiss Team

Key Takeaways

Most supplement manufacturers that conduct qualifying research activities are not claiming the R&D tax credit. The common assumption that IRC Section 41 applies only to pharmaceutical or technology companies is wrong — formulation development, stability testing, and process improvement in dietary supplement manufacturing can all meet the four-part test.
The One Big Beautiful Bill Act, signed July 4, 2025, permanently restored the immediate expensing of domestic R&E expenditures under new Section 174A. For tax years beginning after December 31, 2024, qualifying domestic research costs are fully deductible in the year incurred — no more five-year amortization.
Bottom line: The tax-planning opportunity for supplement manufacturers at the intersection of Section 174A and Section 41 is real, time-sensitive for retroactive elections, and frequently unclaimed. That combination makes it worth a structured analysis.

The dietary supplement industry does not typically think of itself as an R&D-intensive sector. Pharmaceutical companies run clinical trials. Technology companies write algorithms. Supplement manufacturers blend ingredients.

That mental model is costing supplement companies real money.

Formulating a new delivery mechanism for a bioavailable mineral. Running stability testing to establish a shelf-life claim. Developing a manufacturing process that improves yield consistency across production runs. These are not trivial activities. Under the right facts, they are qualified research activities under IRC Section 41 — and the associated costs, now fully deductible under new Section 174A for domestic activity, produce tax savings that most supplement manufacturers have never modeled.

The current legislative environment makes this the right moment to take it seriously.

The R&D Tax Credit: What Supplement Manufacturers Actually Qualify For

The research and development tax credit under IRC Section 41 is a dollar-for-dollar reduction in federal income tax liability. It is not an above-the-line deduction. A $100,000 credit eliminates $100,000 of tax owed — which makes it substantially more valuable than a deduction of equivalent size at any effective tax rate below 100%.

The credit applies to qualified research expenses, which must meet what the IRS calls the four-part test:

Permitted purpose: The research must be directed toward developing or improving a product, process, formula, technique, or software — specifically, improving its functionality, performance, reliability, or quality. Research relating to style, taste, or cosmetic factors does not qualify under IRC Section 41(d)(3)(B).
Elimination of uncertainty: There must be genuine technical uncertainty about the design, capability, or method of achieving the intended result at the outset of the activity.
Process of experimentation: The taxpayer must evaluate one or more alternatives through systematic trial, modeling, or testing — rather than simply applying established procedures.
Technological in nature: The activity must rely on principles of physical, biological, engineering, or computer science.

For supplement manufacturers, the question is not whether the four-part test is stringent. It is whether specific activities undertaken in the ordinary course of product development and manufacturing improvement satisfy it. Many do.

Activities That Frequently Qualify

The following supplement manufacturing activities have the factual profile to support a Section 41 credit claim, subject to the specific facts of each project:

Developing new formulations — ingredient combinations, active compound ratios, or delivery systems (capsules, powders, ready-to-drink) — where the optimal configuration is not known in advance
Conducting stability testing to establish or verify shelf-life claims for new products or formulations
Improving the bioavailability of existing active ingredients through modified delivery mechanisms or excipient selection
Developing manufacturing processes to address consistency, yield, or quality control problems that are not resolved by following a standard procedure
Testing new encapsulation, binding, or coating techniques to improve product performance or stability

Activities That Generally Do Not Qualify

Not all product development costs pass the four-part test. Supplement manufacturers should be clear-eyed about exclusions:

Reformulating a product to improve taste or flavor without a functional or bioavailability objective
Scaling up a proven formulation for larger production runs using established manufacturing procedures
Routine quality control testing on existing products using standard protocols
Market research, consumer surveys, and preference testing

The line between qualifying and non-qualifying activity can be fact-specific. A stability test run to establish a new claim may qualify; a stability test run to confirm a known shelf life under an identical formulation likely does not.

What Section 174A Changed — and Why It Matters for 2025 and Beyond

From 2022 through 2024, the Tax Cuts and Jobs Act required manufacturers to capitalize qualifying R&E expenditures and amortize them over five years for domestic research and 15 years for foreign research, using a midyear convention. The cash flow impact was immediate and significant: a supplement company incurring $500,000 in qualifying domestic R&E in 2022 could deduct only $50,000 that year, deferring $450,000 into future periods.

The One Big Beautiful Bill Act, signed July 4, 2025, reversed this for domestic activity. New IRC Section 174A reinstates immediate expensing for domestic R&E costs effective for tax years beginning after December 31, 2024. Foreign R&E expenditures remain subject to 15-year amortization under the unchanged TCJA rules.

For a supplement manufacturer conducting all R&E domestically, the practical effect is that the full cost of qualifying research activity incurred in 2025 and beyond is deductible in the year it occurs — no capitalization schedule required, no multi-year recovery period.

Taxpayers also retain an election under Section 174A to capitalize domestic R&E costs and amortize them ratably over a period of not less than 60 months, beginning with the month the taxpayer first realizes benefits from the expenditures. This flexibility matters in specific situations — for example, a company projecting a net operating loss in 2025 may prefer to spread the deduction rather than deepen a loss that will be subject to an 80% utilization limitation in future years. Whether to take the immediate deduction or elect amortization requires modeling.

The Small Business Retroactive Election: A Time-Sensitive Opportunity

For supplement manufacturers that qualify as small businesses under the OBBBA’s definition, there is a retroactive relief provision that warrants immediate attention.

Eligible small business taxpayers — those with combined gross receipts of $31 million or less as tested for the 2025 taxable year under the Section 448(c) aggregation rules — may make a special election to retroactively apply Section 174A to domestic R&E expenditures incurred in tax years beginning after December 31, 2021.

In plain terms: a qualifying supplement manufacturer that capitalized and amortized domestic R&E costs in 2022, 2023, and 2024 under the TCJA rules may be able to amend those returns, claim immediate deductions for the previously capitalized amounts, and recover the resulting tax overpayments.

The magnitude of this opportunity depends on the amount of qualifying R&E the company incurred during those years and its effective tax rate in each period. For companies that were actively developing new formulations or improving processes from 2022 to 2024, the analysis is worth completing.

Critical timing note: the window for small businesses to make the retroactive election on amended returns runs from July 4, 2025, through July 4, 2026. Missing this deadline forfeits the retroactive relief.

Coordinating Section 174A and Section 41: The 280C Interaction

The OBBBA reinstated the Section 280C rule that applied prior to the TCJA, and supplement manufacturers claiming both the R&E deduction and the R&D credit on the same expenses must understand how it works.

The amount of domestic R&E expenditures deductible under Section 174A must be reduced by the amount of the research credit claimed. A company with $100,000 in qualifying R&D expenses claiming a $10,000 research credit can deduct only $90,000 of those expenses.

Alternatively, taxpayers may elect under Section 280C(c) to claim a reduced credit — at a rate reduced by the maximum corporate tax rate of 21% — rather than reducing the deduction. The election produces a smaller credit but preserves the full deduction. Whether the deduction reduction or the credit reduction produces the better net outcome depends on the company’s effective tax rate, the relative size of the deduction and the credit, and the year in which each benefit is realized.

This is not an election to make by default. For a supplement manufacturer claiming meaningful Section 41 credits on a substantial base of qualifying R&E, the difference between the two approaches can be material. It requires explicit modeling before a tax return is filed.

Planning for Supplement Manufacturers: Where to Start

The supplement manufacturer’s R&D tax planning analysis has three components that should be addressed together:

Identify qualifying activities. This requires a structured review of product development projects, manufacturing process improvement initiatives, and stability testing programs, evaluated against the Section 41 four-part test. Activities that do not generate contemporaneous documentation of the research question, the approach, and the outcome are harder to defend on examination.
Quantify qualifying expenses. Section 41 qualified research expenses include wages paid to employees directly engaged in qualifying research and their direct supervisors, supply costs consumed in the research, and 65% of qualifying contract research expenses — including amounts paid to third-party formulators or testing laboratories conducting eligible work on behalf of the manufacturer.
Model the 174A/41/280C interaction. The deduction, the credit, and the coordination rule produce a combined tax result that is different from what either provision produces in isolation. The right position depends on the company’s projected taxable income, existing NOL balances, and effective tax rate.

Supplement manufacturers that have not formally reviewed their R&D activities against the Section 41 framework are leaving a dollar-for-dollar credit on the table — one that, for small businesses, can also be applied against payroll taxes rather than income taxes if the company is pre-profit or has limited tax liability. That payroll tax offset provision, under IRC Section 41(h), makes the credit accessible even to companies that are not yet generating taxable income.

Wiss works with supplement manufacturers and consumer health brands on tax strategy, R&D credit studies, and the coordination planning that the current rules require. If your company is developing new formulations or improving manufacturing processes and has not formally assessed its Section 41 eligibility under the OBBBA, that analysis is overdue.

This article reflects federal tax law as of the date of publication, including provisions enacted under the One Big Beautiful Bill Act signed July 4, 2025. State conformity to Section 174A varies and must be evaluated on a case-by-case basis. This content is for informational purposes only and does not constitute tax advice. Consult a qualified tax advisor before making elections or filing amended returns.